DOI: https://doi.org/10.21203/rs.3.rs-73476/v1
Background: Metabolic syndrome and obesity are risk factors for developing type 2 diabetes mellitus and/or cardiovascular disease, especially stroke. Obesity-associated diseases account for a large portion of public health challenges. Among obesity-related disorders, a direct and independent relationship has been ascertained for colorectal cancer.
Objective: The aim of this study was to determine the prevalence of metabolic syndrome and other cardiovascular risk factors, including dyslipidemia, hypertension, dietary and exercise practices, tobacco use and body mass index in individual with colorectal cancer patients attending Tikur Anbessa Hospital Oncology department, Addis Ababa.
Methods: A comparative cross-sectional study was conducted from February, 2016 to Jun 2017 on 79 patients attending the Oncology clinic at Tikur Anbessa Hospital. Components of metabolic syndrome, including fasting serum glucose, serum triglyceride, serum high density lipoprotein, blood pressure and waist circumference, was measured in all of the patients. In addition, serum total cholesterol, serum low density lipoprotein was measured with 5010 photometers, and information gathered on smoking and other lifestyle practices, including diet and exercise.
Result: Of 79 patients, 23 had metabolic syndrome (MS); 58.2% males; mean-age 48.6 years with range (26 to 78) and 41.8 % Female; mean age 44.6 years with range (20 to 78). Among the MS group, 45.6 % had high blood pressure, 26.6 % had increased waist circumference, 67.1% had serum blood glucose level greater than 100 mg/dL, 68.3 % had low high-density lipoprotein cholesterol level, 57 % had increased triglyceride level, and 3.8 % were obese [body mass index (BMI) >30 kg/m2]. 29 % presented 3 criteria of MS. From total colorectal cancer patients 53.2 % had colon cancer, 46.8 % had rectal cancer and 12.7 % had stage I,40.5 % had stage II (IIa,IIb & IIc), 25.3 % had stage III (a,b,c) and 21.5 % had stage IV disease.
CONCLUSION: MS is positively associated with adenomas and colorectal cancer. However, there is not enough information in Ethiopia to justify screening in patients with MS. To our knowledge, no previous study has evaluated this association in Ethiopian patients.
This preprint is available for download as a PDF.